Six-Month Response to Delamanid Treatment in MDR TB Patients

Six-Month Response to Delamanid Treatment in MDR TB Patients

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability...

Full description

Bibliographic Details
Main Authors: Cathy Hewison, Gabriella Ferlazzo, Zaza Avaliani, Armen Hayrapetyan, Sylvie Jonckheere, Zarema Khaidarkhanova, Erika Mohr, Animesh Sinha, Alena Skrahina, Debrah Vambe, Irina Vasilyeva, Nathalie Lachenal, Francis Varaine
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2017-10-01
Series:Emerging Infectious Diseases
Subjects:
Tuberculosis
multidrug resistance
delamanid
drug therapy
combination
antitubercular agents
Online Access:https://wwwnc.cdc.gov/eid/article/23/10/17-0468_article

Internet

https://wwwnc.cdc.gov/eid/article/23/10/17-0468_article

Similar Items